NEW YORK (GenomeWeb) – Cantor Fitzgerald has initiated coverage of NeoGenomics with an Overweight rating and a price target of $11.

The investment bank said NeoGenomics' "transformational acquisition" of Clarient last year has moved the company into a leadership position in the cancer diagnostics market, "with improved economies of scale, a broadened testing portfolio, an expanded geographic reach, and ongoing relationship with GE Healthcare."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.